Ipsen: Sales In The 3rd Quarter And First Nine Months Of 2014
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2014.
Active substances and raw materials. Drug-related sales are affected by an unfavorable effect arising from the change in methodology for the consolidation of sales of the Swiss company Linnea. Indeed, sales of active ingredients and raw materials made by Linnea, partner on which Ipsen and the Schwabe Group exercise joint control, will from now on be consolidated under the equity method of accounting2.
Help employers find you! Check out all the jobs and post your resume.
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the third quarter and first nine months of 2014.
Active substances and raw materials. Drug-related sales are affected by an unfavorable effect arising from the change in methodology for the consolidation of sales of the Swiss company Linnea. Indeed, sales of active ingredients and raw materials made by Linnea, partner on which Ipsen and the Schwabe Group exercise joint control, will from now on be consolidated under the equity method of accounting2.
Help employers find you! Check out all the jobs and post your resume.